Search
eluxadoline (Viberzi)
Indications:
- irritable bowel syndrome with diarrhea [1,2]
Contraindications:
- history of bile duct obstruction
- history of pancreatitis
- history of cholecystectomy
- severe liver impairment
- severe constipation
- > 3 alcoholic beverages per day
Dosage:
- 75 mg PO BID with food
Tabs: 75 mg
Adverse effects:
- constipation
- nausea
- abdominal pain
- spasm in the sphincter of Oddi, resulting in pancreatitis
- increased risk of pancreatitis in patients without a gallbladder [3]
Mechanism of action:
- activates receptors in the nervous system that can lessen bowel contractions
- mixed opioid effects [2]
General
gastrointestinal agent
neurologic agent
References
- FDA News Release. May 27, 2015
FDA approves two therapies to treat IBS-D
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm448328.htm
- Lembo AJ, Lacy BE, Zuckerman MJ et al
Eluxadoline for Irritable Bowel Syndrome with Diarrhea.
N Engl J Med 2016; 374:242-253. January 21, 2016
PMID: 26789872
http://www.nejm.org/doi/full/10.1056/NEJMoa1505180
- FDA Safety Alert. 03/15/2017
Viberzi (eluxadoline): Drug Safety Communication - Increased Risk
of Serious Pancreatitis In Patients Without A Gallbladder.
https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm546771.htm